Just figured to repost duckduffer's entry from an earlier post wrt EXEL's last known public posture toward it's financial health.There seems to be a persistent short element that would cast a pall of continued despairing doubt and misinformation upon the debt/cash ratio of Exelixis. Although ending 2013 with $400M seems a bit optimistic to me - particularly with EXEL-sponsored pivotal trials in HCC and RCC planned for later this year, and a previously disclosed marketsharing financial committment w/ Roche to initiate by year's end for GDC-0973. For the record, here's the last public reporting, and I'm posting this only because it's easier for me to find if I need to...
"From the 4Q PR-
Cash and cash equivalents, short- and long-term investments and short- and long-term restricted cash and investments totaled $634.0 million at December 31, 2012, compared to $283.7 million at December 31, 2011.
Exelixis expects its cash and cash equivalents, short- and long-term investments and short- and long-term restricted cash and investments to be approximately $400 million at the end of 2013. "
"It's called a balance sheet. It has another side...known in the parlance as Liabilities"
No offense, but the balance sheet analysis is forensic accounting and of little value with a speculative developmental biotech.
Science and cash. More specifically how much cash do they have and how much cash do they need. Those are your fundamentals with this type of investment.
"..known in the parlance as Liabilities. You might want to look at those as well"
Of course. But of far greater value to me is the value of that first-approved MET inhibiting dirty TKI - Cabo. In the spirirt of endeavor, aren't we all a bit inclined to look past the risk...and toward the potential reward? For my money - Cabo is the most interesting IP in all of biotech right now. If the Cabo bone effect phenom holds on current course, none of EXEL's debt will matter in two year's time.
That debt won't exist. Neither will EXEL.